Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16452 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Qinghua Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Innogen pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Aims
This Phase 1 study aimed to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single‐dose subcutaneous Efsubaglutide Alfa, a novel glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), in healthy participants. Materials and Methods This randomised, double‐blind, placebo‐controlled, single‐dose escalation study was conducted at a single centre. A total of 48 healthy adults were randomised (6:2) across six dose cohorts (0.375, 0.75, 1.5, 3, 6 and 9 mg) to receive Efsubaglutide Alfa or placebo. Safety, PK and PD parameters were assessed.
Results
Efsubaglutide Alfa exhibited dose‐proportional PK, with a median T max of 47.5–71.7 h and a mean half‐life ( T 1/2 ) of 121.4 h. Exposure increased linearly across doses ( C max : 37.1–832.4 ng/mL, AUC 0–∞ : 8699.6–193446.6 ng/mL·h). No serious AEs occurred; mild‐to‐moderate gastrointestinal AEs (nausea, vomiting, decreased appetite) were the most common in Efsubaglutide Alfa‐treated subjects. Post‐dose, fasting plasma glucose transiently declined on Day 1, returned to baseline by Day 2, and remained within −0.8 to +1.9 mmol/L relative to baseline (within expected physiological variability) through Day 28. Fasting insulin and C‐peptide levels slightly increased on Day 1, normalised by Day 2, and remained stable. At Day 2, OGTT revealed reduced glucose excursions in Efsubaglutide Alfa recipients ( p = 0.0150 vs. placebo; AUC ~0.7 mmol/L·2 h lower), while insulin and C‐peptide levels remained unchanged. Dose‐dependent weight loss peaked at Day 4–7, with up to a 4.0% reduction ( p < 0.0001) at the higher dose, followed by a gradual return towards baseline by Day 28.
Conclusions
Efsubaglutide Alfa was well tolerated in healthy participants, with a favourable PK and PD profiles that support further clinical development in type 2 diabetes and metabolic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China.
- Innogen Pharmaceutical Co., Ltd, Shanghai, China.
- Department of Endocrinology and Metabolism, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
- Department of Clinical Base, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
ORCID-Profile: Qinghua Wang, Dalong Zhu
Förderung
- Innogen pharmaceutical Co., Ltd
Zitieren
APA
Wang, Q., Cui, Q., Xu, Y., Prud'homme, G. J., Yang, Y., Zhu, D., Li, Y., Yang, Y., & Li, J. (2025). Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16452
Vancouver
Wang Q, Cui Q, Xu Y, Prud'homme GJ, Yang Y, Zhu D, et al. Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16452
BibTeX
@article{Wang2025,
author = {Wang, Qinghua and Cui, Qiaoli and Xu, Yulong and Prud'homme, Gerald J and Yang, Yuanxun and Zhu, Dalong and Li, Yiming and Yang, Yehong and Li, Juan},
title = {Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16452}
}
EUVIMED